1.11
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
Small Cap Basic
Monthly Subscription
for only
|
Big Cap Pro
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Proteostasis Therapeutics Inc | PTI | NASDAQ | Common Stock |
Price Change | Change Percent | Stock Price | Last Traded ![]() |
|
---|---|---|---|---|
0.00 | 0.0% | 1.11 | 19:00:00 |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.11 | 1.11 |
Bid Price | Ask Price | Spread | News | |
---|---|---|---|---|
1.12 | 1.14 | 0.02 | - | - |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 1.11 | USD |
Proteostasis Therapeutics Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 144.81k | 130.46k | 2.58M | $ 5.00M | $ - | -23.00 | -1.50 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | 0.00% | - | - |
Proteostasis Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PTI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Month | 1.17 | 1.20 | 1.10 | 1.11 | 2,107,079 | -0.06 | -5.13% |
3 Months | 1.11 | 1.31 | 0.9384 | 1.12 | 647,966 | 0.00 | 0.0% |
6 Months | 1.56 | 1.94 | 0.9384 | 1.28 | 719,979 | -0.45 | -28.85% |
1 Year | 2.00 | 2.20 | 0.87 | 1.44 | 917,457 | -0.89 | -44.5% |
3 Years | 4.29 | 10.74 | 0.61 | 3.39 | 1,593,438 | -3.18 | -74.13% |
5 Years | 8.00 | 20.63 | 0.61 | 3.76 | 1,070,822 | -6.89 | -86.13% |
Proteostasis Therapeutics Description
Proteostasis Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (CF) through theratyping, or the process of matching modulators to individual response to treatment regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. All of the company's revenue is collaboration or license revenue earned from activities in the United States. |